Autologous blood transfusion within last  days or plan to donate autologous blood prior to surgery
Appropriate antibiotics, blood products, anti-emetics, fluids, electrolytes and general supportive care are to be used as necessary
Acceptable blood work
Agreement not to donate blood or blood products during the study and for  months after discontinuation of vismodegib
Refusal to potentially receive blood products and/or have a hypersensitivity to blood products
Abnormal blood results
Study subjects with known chronic infection with HIV, hepatitis B or C, since these infections may interfere with the evaluation of vaccine-induced immune responses. Infectious disease testing will be performed whenever a study subject exhibits clinical signs of infection or to confirm a history of infection. Testing will also be performed for all study subjects undergoing leukapheresis, as required by the blood bank for autologous blood products (standard donor transmissible disease testing)
Patients who have eligible blood counts within  weeks from enrollment will not be considered ineligible if subsequent blood counts prior to enrollment fluctuate and become ineligible up until the time of enrollment
Difficulty providing blood samples.
Patients who are receiving licensed cord blood products (only)
Patients who are receiving unlicensed cord blood products from other banks (only)
Patients who are receiving cord blood products that will be \manipulated\ post-thaw (e.g., ex vivo expansion, incubation in vitro, etc.)
To be performed within  days prior to day  of protocol therapy: platelets >= ,/mm^\r\n* NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelines
To be performed within  days prior to day  of protocol therapy: hemoglobin (HgB) >= . g/dL\r\n* NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelines
Patients who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
Blood counts are not required to be normal prior to enrollment on trial
Received blood products within  days to first dosing
Patients with known sensitivities to albumin, blood, or blood products
Blood transfusion (including blood products) within  week of screening.
Patients who decline possible transfusion of blood products will be excluded
Patients must be willing to receive transfusions of blood products
Agreement not to donate blood or blood products during the study and for  months after discontinuation of vismodegib
ELIGIBILITY CRITERIA AT THE TIME OF APHERESIS: Patients must NOT have an active severe infection defined as:\r\n* A positive blood culture within  hours of blood draw OR\r\n* A fever above . C AND clinical signs of infection within  hours of blood draw
Relapsed/refractory MCL: Patients must be willing to receive transfusions of blood products
Newly diagnosed MCL: Patients must be willing to receive transfusions of blood products
Blood counts no restrictions
Appropriate antibiotics, blood products, antiemetics, fluids, electrolytes and general supportive care are to be used as necessary
DONOR: Has not donated blood products to recipient
Patients who have eligible blood counts within  weeks from enrollment will not be considered ineligible if subsequent blood counts prior to enrollment fluctuate and become ineligible up until the time of enrollment
Donation of blood or blood products in excess of  mL within  days of screening
Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors within  weeks prior to study Day .
Agreement to provide blood samples for pharmacodynamic studies utilizing Peripheral Blood Mononuclear Cells (PMBCs) as outlined in the protocol
Difficulty providing blood samples.
A recognized single pathogen cultured from  or more blood cultures; OR
Unwillingness to receive infusion of blood products.
DONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including:\r\n* Age >=  years old;\r\n* Normal hemogram (white blood cells [WBC] .-. x ^/mm^; platelet count , to ,/mm^ ; hemoglobin/hematocrit; .- g/dl,  to % \r\n* Not pregnant or lactating;\r\n* Not human immunodeficiency virus (HIV)-, HIV-, hepatitis C virus (HCV), hepatitis B core or human T-cell lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by RWJ Blood Services;\r\n* No uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes;\r\n* Meet other blood bank criteria for blood product donation (as determined by RWJ Blood Center screening history and laboratory studies)
Patients must be willing to receive transfusions of blood products.
Unwillingness to receive infusion of blood products according to the protocol.
Subjects who have received any anticancer therapy (including surgery, percutaneous ethanol injection, radio frequency ablation, transarterial [chemo] embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or radiotherapy) or any blood enhancing treatment (including blood transfusion, blood products, or agents that stimulate blood cell production, eg, granulocyte colony-stimulating factor [G-CSF]) within  days prior to randomization
Subject is unwilling to allow transfusion of blood or blood products.
Has not donated blood products to patient
Within  hour (h) of initiating study treatment: Hemoglobin (Hgb) >= . g/dL; Note: transfusions of blood and blood products as well as growth factor support are prohibited within  days prior to the first dose of study treatment
Within  h of initiating study treatment: Platelets >= ,/mm^; Note: transfusions of blood and blood products as well as growth factor support are prohibited within  days prior to the first dose of study treatment
Consent to potential need for transfusion of blood products
Patients must be willing to receive transfusions of blood products
Anticipated blood donation within the next  days
Transfusion of blood products are not allowed to normalize blood parameters within  weeks of the first radium treatment
Have a cancer of the blood
Patients must be willing to receive transfusions of blood products
Absence of gross blood in stool; red blood on toilet paper only acceptable.
All patients should agree not to donate blood products for  months after stopping sonidegib
Hematopoietic growth factors, transfusions of blood or blood products within  week
Positive blood culture within  hours of study enrollment.
Hematopoietic growth factors, transfusions of blood or blood products within  week
DONOR: meet other blood bank criteria for blood product donation (as determined by NBAH Blood Center screening history and laboratory studies)
Abnormal blood test results
Patients must be willing to receive transfusions of blood products
Agreement not to donate blood or blood products during the study and for  months after discontinuation of vismodegib
Acceptable blood test results.
History of anaphylactic reaction(s) to blood or blood components.
Refusal to receive allogenic transfusion of blood-derived products.
Participants who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
Adequate availability of sickle trait negative, leukoreduced, Blood type (ABO) blood group, Rhesus factor D (Rh (D)) compatible, unexpired replacement RBC products.
History of expectoration of blood within  month prior to study start or blood clotting problems.
Participants who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
DONOR: Has not donated blood products to patient
Patients must be willing to receive transfusions of blood products
Research blood including  mL of blood in a heparinized tube for peripheral blood mononuclear cell (PBMC) collection and  mL of blood for serum collection (generally in a red top tube) within  days of leukapheresis collection
Previous treatment with pathogen-reduced blood products
History of blood clot;
Must be capable of undergoing a single standard  blood volume leukapheresis or donation of one unit of whole blood
DONOR: has not donated blood products to patient
Women with blood pressures above / or below /
Estimated blood loss (EBL) >  liter
Difficulty providing blood samples.
Patients with hemoglobin levels more than or equal to  g/dl would be eligible for the study even if they are currently receiving blood products
Transfusion of blood products or intravenous immune globulin within  months of study entry
Negative fecal occult blood test
Must be willing to have about  ml of blood drawn at ,  and  months and about - ml of blood at  and  months
Eligible for donations of human blood and blood components according to local requirements and regulations
Must be willing to have about  ml of blood (approximately  teaspoons) drawn at  and  months and about - ml of blood (approximately - teaspoons) at  and  months
Agreement not to donate blood or blood products during the study and for  months after the last dose
Patients with known sensitivities to albumin, blood, or blood products
Peripheral Blood Samples:
Abnormal blood results
Patient agrees to the collection and testing of their blood and is willing and able\n             to provide approximately mL blood draw(s) at: